MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kharasch, E. D.
Right arrow Articles by Novak, R. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kharasch, E. D.
Right arrow Articles by Novak, R. F.

Inhibition of microsomal oxidative drug metabolism by 1,4-bis (2-[(2- hydroxyethyl)amino]-ethylamino)-9,10-anthracenedione diacetate, a new antineoplastic agent

ED Kharasch and RF Novak

The effects of 1,4-bis(2-[(2-hydroxyethyl)amino]-ethylamino)-9,10- anthracenedione diacetate (HAQ) on rabbit liver microsomal oxidative drug metabolism were investigated. HAQ was found to inhibit O- dealkylase and N-demethylase activities in phenobarbital-induced microsomes, and aryl hydrocarbon hydroxylase activity in beta- naphthoflavone-induced microsomes. The inhibition was noncompetitive with respect to substrate concentration, with inhibitory constant (Ki) values of 2.9, 2.6, and 3.0 mM for p-nitroanisole, N,N-dimethylaniline, and benzo[a]pyrene, respectively. In contrast, HAQ failed to inhibit p- nitroanisole metabolism when the reaction was supported with cumene hydroperoxide. HAQ also inhibited basal and substrate-stimulated microsomal NADPH oxidation. The degree of inhibition of NADPH oxidation and product formation were comparable. These data, in conjunction with the results of previous studies, suggest that HAQ inhibits electron transfer by microsomal NADPH-cytochrome P-450 reductase, diminishing electron flow to cytochrome P-450 and thereby inhibiting substrate metabolism. This mechanism differs markedly from that for inhibition of drug metabolism by other quinones, such as menadione, in which accelerated electron flow through P-450 reductase to the quinone diverts reducing equivalents from cytochrome P-450.

Volume 22, Issue 2, pp. 471-478, 09/01/1982
Copyright © 1982 by American Society for Pharmacology and Experimental Therapeutics







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1982 by the American Society for Pharmacology and Experimental Therapeutics